叶娜

叶娜.JPG

姓名:叶娜

职务职称:博士,特聘副教授,硕士生导师

联系电话:0512-65881161

联系邮箱:yena@suda.edu.cn

联系地址:苏州市工业园区仁爱路199号药学院云轩楼1225

 

个人简介:

一、学习与工作经历

2016.9–至今:  苏州大学,药学院,特聘副教授

2013.6–2016.8:美国德州大学医学分部,博士后

2008.09-2013.06中国科学院上海药物研究所,药物化学,理学博士

2004.09-2008.07沈阳药科大学,国家基础药学理科基地班,理学学士

 

二、研究方向

1)靶向神经精神性重大疾病的药物研发

2)抗肿瘤药物的设计与合成

3) 有机方法学在药物研发中的应用

 

三、主要学术科研成果

曾参与国家自然科学基金重大专项、美国NIHCPRIT等项目研究,发表SCI论文20余篇,其中第一作者10参与申报国际发明专利1美国专利1项、中国发明专利5项,其中1项中国专利已授权。并编写专著《新药研发案例研究:明星药物如何从实验室走向市场》第十章-氟西汀。另外,设计开发的靶向聚腺苷二磷酸核糖聚合酶PARP抑制剂SOMCL-9112作为抗肿瘤候选药物,已申报化学药品1.1类新药希明哌瑞及其片剂,经CFDA快速审批,已获得临床实验批件 (批件号2016L02538),并即将进入临床I期研究。

1、代表性论文

1)Ye, N.; Neumeyer, J. L.; Baldessarini, R. J.; Zhen, X.; Zhang, A. Update 1 of: Recent Progress in Development of Dopamine Receptor Subtype-selective Agents: Potential Therapeutics for Neurological and Psychiatric Disorders. Chem. Rev., 2013, 113, PR123-178.

2)Ye, N.; Zhu, Y.; Chen, H.; Liu, Z.; Mei, F. C.; Wild, C.; Chen, H.; Cheng, X.; Zhou, J. Structure–Activity Relationship Studies of Substituted 2-(Isoxazol-3-yl)-2-oxo-N’-phenyl-acetohydrazonoyl Cyanide Analogues: Identification of Potent Exchange Proteins Directly Activated by cAMP (EPAC) Antagonists. J. Med. Chem., 2015, 58, 6033-6047.

3)Ye, N.; Ding, Y.; Wild, C.; Shen, Q.; Zhou, J. Small molecule inhibitors targeting activator protein 1 (AP-1). J. Med. Chem., 2014, 57, 6930-6948.

4)Ye, N.; Chen, C. H.; Chen, T.; Song, Z.; He, J. X.; Huan, X. J.; Song, S. S.; Liu, Q.; Chen, Y.; Ding, J.; Xu, Y.; Miao, Z. H.; Zhang, A. Design, Synthesis, and Biological Evaluation of a Series of Benzo[de][1,7]naphthyridin-7(8H)-ones bearing a Functionalized Longer Chain Appendage as Novel PARP1 Inhibitors. J. Med. Chem., 2013, 56, 2885-2903.

5)Zhang, H.; *Ye, N.; Zhou, S.; Guo, L.; Zheng, L.; Liu, Z.; Gao, B.; Zhen, X.; Zhang, A. Identification of N-Propylnoraporphin-11-yl 5-(1,2-Dithiolan-3-yl)pentanoate as a New Anti-Parkinson’s Agent Possessing a Dopamine D2 and Serotonin 5-HT1A Dual-Agonist Profile. J. Med. Chem., 2011, 54, 4324–4338. (* 并列作者)

6)Ye, N.; Song, Z.; Zhang, A. Dual Ligands Targeting Dopamine D2 and Serotonin 5-HT1A Receptors as New Antipsychotical or Anti-Parkinsonian Agents. Curr. Med. Chem., 2014, 21, 437-457.

7)Ye, N.; Shi, P.-Y.; Zhou, J. Therapetic Potential of Spirooxindoles as Antiviral Agents. ACS Infect. Dis., 2016, 2, 382-292.

8)Ye, N.; Wu, Q.; Zhu, L.; Zheng, L.; Gao, B.; Zhen, X.; Zhang, A. Further SAR Study on 11-O-substituted Aporphine Analogues: Identification of Highly Potent Dopamine D3 Receptor Ligands. Bioorg. Med. Chem., 2011, 19, 1999–2008.

9)Ye, N.; Xu, X.; Li, F.; Ning, M.; Liu, Z.; Cao, Y.; Leng, Y.; Zhang, A. Investigation on the Oxidation of Aryl Oxiranylmethanols and the Synthesis of 2-Aryl-N-thiazolyl-oxirane-2-carboxamides as Glucokinase Activators. Tetrahedron Lett., 2012, 53, 4738–4742.

10)Ye, N.; Zhou, J. KRAS - An Evolving Cancer Target. Austin J. Cancer Clin. Res., 2014, 1, 1004.

11)Liu, Z.; Zhang, H.; Ye, N.; Zhang, J.; Wu, Q.; Sun, P.; Li, L.; Zhen, X.; Zhang, A. Synthesis of Dihydrofuroaporphine Derivatives: Identification of a Potent and Selective Serotonin 5-HT1A Receptor Agonist. J. Med. Chem. 2010, 53, 1319–1328.

12)Wild, C.; Zhu, Y.; Ye, N.; Mei, F.; Ynalvez, M.; Chen, H.; Cheng, X.; Zhou, J. Functionalized N,N-Biarylamines as Potent and Selective EPAC2 Inhibitors. ACS Med. Chem. Lett. 2016, 7, 460-464.
 

2、专利

1)张翱,缪泽鸿,叶娜,宦霞娟, 宋子兰,陈川惠子,陈奕,丁健:哌嗪并三嗪类化合物、制备方法及用途。WO 2014019468 A1, 2013

2)Neamati, N.; Zhou, J.; Kuang, Y.; Ye, N. Compositions and Methods for Treating and Preventing Cancer. US Provisional patent filed on 5/20/2015.

3)张翱,镇学初, 叶娜,陈学涛,余蕾平:一类新型阿朴菲类化合物及其制备方法和用途。CN 1025321042010。(已授权)

4)张翱,镇学初,叶娜,张海,李令勇,朱丽媛,蔡文倩:硫辛酸-阿朴菲共轭化合物、其药物组合物及其用途。CN 102675300A2011

5)张翱,缪泽鸿,叶娜,宦霞娟, 宋子兰,陈川惠子,陈奕,丁健:具有桥环结构的稠环哒嗪酮类化合物及其制备方法和用途。CN 1035707302012

6)张翱,缪泽鸿,叶娜,宦霞娟, 宋子兰,陈川惠子,陈奕,丁健:稠环哒嗪酮类化合物及其制备方法和用途。公开号:CN 1035707222012

7)张翱,缪泽鸿,叶娜,宦霞娟, 宋子兰,陈川惠子,陈奕,丁健:一类哒嗪酮类化合物及其制备方法和用途。CN103833756, 2012